Safety of allergen immunotherapy in children.

IF 3 4区医学 Q2 ALLERGY

Current Opinion in Allergy and Clinical Immunology Pub Date : 2023-12-01 Epub Date: 2023-10-17 DOI:10.1097/ACI.0000000000000945

Kristin A Schmidlin, David I Bernstein

{"title":"Safety of allergen immunotherapy in children.","authors":"Kristin A Schmidlin, David I Bernstein","doi":"10.1097/ACI.0000000000000945","DOIUrl":null,"url":null,"abstract":"Purpose of review: The current review discusses allergen immunotherapy (AIT) safety in children.Recent findings: AIT is a well tolerated and effective treatment for pediatric allergic conditions. While mostly well tolerated, severe reactions and near fatal reactions may occur with subcutaneous immunotherapy (SCIT) once in every 160 000 visits. Sublingual immunotherapy (SLIT) is associated more with local side effects, but severe systemic reactions, including anaphylaxis, have been rarely reported. Providing informed consent, recognizing risk factors for severe systemic reactions, such as severe or uncontrolled asthma, and mitigating the risk of severe reactions are important components to improving the safety of AIT.Summary: Overall, AIT is well tolerated in children, and data suggest that the incidence of systemic reactions in children receiving SCIT is no less than mixed populations of adult and pediatric patients. SLIT carries less risk for systemic reactions, and local oral site-application reactions are usually mild and resolve within 15 days of treatment.","PeriodicalId":10956,"journal":{"name":"Current Opinion in Allergy and Clinical Immunology","volume":" ","pages":"514-519"},"PeriodicalIF":3.0000,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Opinion in Allergy and Clinical Immunology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/ACI.0000000000000945","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/10/17 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ALLERGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of review: The current review discusses allergen immunotherapy (AIT) safety in children.

Recent findings: AIT is a well tolerated and effective treatment for pediatric allergic conditions. While mostly well tolerated, severe reactions and near fatal reactions may occur with subcutaneous immunotherapy (SCIT) once in every 160 000 visits. Sublingual immunotherapy (SLIT) is associated more with local side effects, but severe systemic reactions, including anaphylaxis, have been rarely reported. Providing informed consent, recognizing risk factors for severe systemic reactions, such as severe or uncontrolled asthma, and mitigating the risk of severe reactions are important components to improving the safety of AIT.

Summary: Overall, AIT is well tolerated in children, and data suggest that the incidence of systemic reactions in children receiving SCIT is no less than mixed populations of adult and pediatric patients. SLIT carries less risk for systemic reactions, and local oral site-application reactions are usually mild and resolve within 15 days of treatment.

查看原文本刊更多论文

儿童过敏原免疫疗法的安全性。

综述目的：本综述讨论儿童过敏原免疫疗法（AIT）的安全性。最近的发现：AIT是一种耐受性良好且有效的儿童过敏性疾病治疗方法。虽然大多数耐受性良好，但皮下免疫疗法（SCIT）每160例中可能发生一次严重反应和近乎致命的反应 000次访问。舌下免疫疗法（SLIT）更多地与局部副作用有关，但包括过敏反应在内的严重全身反应很少报道。提供知情同意书，识别严重全身反应的风险因素，如严重或不受控制的哮喘，并降低严重反应的风险，是提高AIT安全性的重要组成部分，数据表明，接受SCIT的儿童全身反应的发生率不低于成人和儿童患者的混合人群。SLIT的全身反应风险较小，局部口服部位应用反应通常较轻，在15分钟内解决治疗天数。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Opinion in Allergy and Clinical Immunology 医学-过敏

CiteScore

5.90

自引率

3.60%

发文量

109

审稿时长

6-12 weeks

期刊介绍： This reader-friendly, bimonthly resource provides a powerful, broad-based perspective on the most important advances from throughout the world literature. Featuring renowned guest editors and focusing exclusively on one to three topics, every issue of Current Opinion in Allergy and Clinical Immunology delivers unvarnished, expert assessments of developments from the previous year. Insightful editorials and on-the-mark invited reviews cover key subjects such as upper airway disease; mechanisms of allergy and adult asthma; paediatric asthma and development of atopy; food and drug allergies; and immunotherapy.